SB2762 amends multiple Illinois statutes to expand and update required health insurance benefits for public employers and health plans. The bill adds new mandates for coverage of medically prescribed seizure detection devices and preeclampsia biomarker testing, while also revising existing required-benefit cross-references in the Counties Code, Illinois Municipal Code, School Code, Health Maintenance Organization Act, Limited Health Service Organization Act, Voluntary Health Services Plans Act, and related provisions of the Illinois Insurance Code.
The seizure detection device provision requires group and individual accident and health insurance policies and managed care plans amended, delivered, issued, or renewed on or after January 1, 2029 to cover medically prescribed seizure detection devices, including related technology, apps, services, or subscriptions. It also bars prior authorization for covered devices and limits cost-sharing to no more than $50 per plan year, except where that would jeopardize high-deductible health plan/HSA eligibility. The preeclampsia biomarker testing mandate applies to policies and plans on or after January 1, 2028 and requires coverage without cost-sharing for predictive screening in asymptomatic individuals and for diagnosis and management when symptoms are present.
Impact
The bill expands state-mandated health coverage in Illinois and applies those mandates across both private insurance and public employer self-insured plans. It specifically amends county, municipal, and school employee health benefit statutes to incorporate the new insurance-code requirements, and it updates HMO and limited health service organization provisions so those entities are also subject to the new coverage rules. The Department of Insurance is assigned enforcement authority, and the bill preserves the state’s exclusive power over these benefit requirements for home rule units. It also adds new statutory sections to the Insurance Code and revises numerous cross-references to keep the mandated-benefit framework current.
Sentiment
The available record shows no committee transcripts or recorded votes, so there is no direct evidence of debate, opposition, or support in the materials provided. Based on the bill text alone, the measure appears to be framed as a health-benefit expansion focused on access to medically necessary devices and prenatal risk screening. The absence of recorded controversy suggests either limited documented discussion or that the bill moved without publicly captured floor or committee debate in the provided materials.
Contention
The main policy tensions likely center on insurance-mandate costs, administrative burden, and the scope of required coverage. Insurers and employer plan sponsors may be concerned about premium impacts, utilization management limits, and the $50 annual cost-sharing cap for seizure detection devices, while advocates for patients with epilepsy and pregnant individuals at risk of preeclampsia would likely support the access protections. A further point of technical contention is the bill’s interaction with high-deductible health plans and health savings account eligibility, which the bill explicitly preserves by carving out conflicting coverage requirements.